Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Guselkumab (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms DISC 2; Discover 2
- Sponsors Janssen Research & Development; Janssen-Cilag
- 01 Jan 2024 Results of post hoc analysis, assessing relationship between earlier clinical improvement and radiographic progression, published in the Clinical Rheumatology
- 15 Nov 2023 Results of post hoc pooled analysis assessing PsA patients with substantial fatigue at baseline , relationships between early fatigue improvement and disease control at 1year, were presented at the ACR Convergence 2023.
- 15 Nov 2023 Results of post hoc pooled analysis (n=473) assessing the impact on patient reported outcomes and individual entheseal points have differential frequency of involvement in patients with active psoriatic arthritis from DISCOVER-1 and DISCOVER-2 studies, presented at the ACR Convergence 2023.